The Oncology (TOI) Fundamental Analysis: Revenue, Earnings & Valuation

5.99 / 10

Netural

Fundamental assessment is moderate with a 5.99 score. PB‑ROE and Asset‑MV are strong contributors, while Revenue‑MV is average. Cash‑MV and Cash‑UP are weak, and earnings growth is modest. Overall fundamentals are balanced but not compelling.

Analysis Checks(3/10)

Revenue-MV

Value1.10

Score1/3

Weight11.34%

1M Return3.16%

Net cash flow from operating activities per share (YoY growth rate %)

Value29.02

Score1/3

Weight2.85%

1M Return0.81%

PB-ROE

Value0.58

Score3/3

Weight33.28%

1M Return8.31%

Basic earnings per share (YoY growth rate %)

Value23.94

Score1/3

Weight2.17%

1M Return0.59%

Total profit (YoY growth rate %)

Value6.07

Score1/3

Weight4.96%

1M Return1.41%

Net cash flow from operating activities (YoY growth rate %)

Value7.35

Score2/3

Weight5.52%

1M Return1.55%

Cash-UP

Value-0.15

Score1/3

Weight2.26%

1M Return0.66%

Diluted earnings per share (YoY growth rate %)

Value23.94

Score1/3

Weight2.36%

1M Return0.65%

Asset-MV

Value-0.55

Score3/3

Weight39.92%

1M Return9.13%

Cash-MV

Value-1.23

Score0/3

Weight-4.65%

1M Return-1.72%

Is TOI undervalued or overvalued?

TOI scores 5.99/10 on fundamentals and holds a Fair valuation at present. Backed by its 0.00% ROE, -12.06% net margin, -5.82 P/E ratio, -18.61 P/B ratio, and 23.94% earnings growth, these metrics solidify its Netural investment rating.